Join
Live feed
·
PRReleasevia Quantisnow
Acumen Pharmaceuticals Inc. logo

Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer's Disease

ByQuantisnow·Wall Street's wire, on your screen.
ABOS· Acumen Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ABOS (Acumen Pharmaceuticals Inc.) and more on Quantisnow.